| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
BRD9 (Bromodomain-containing protein 9).
|
|---|---|
| ln Vitro |
PROTAC BRD9 Degrader-4 exhibits potent in vitro degradation activity against BRD9 in cancer cells. It selectively binds to BRD9 and recruits an E3 ubiquitin ligase, leading to ubiquitination and proteasomal degradation of BRD9.
|
| ln Vivo |
No specific in vivo activity has been reported for this degrader; its in vivo efficacy is being studied for cancer research applications. It is currently under investigation for its ability to inhibit tumor growth in preclinical models.
|
| Enzyme Assay |
N/A; as a complete PROTAC degrader, its binding to both BRD9 and an E3 ligase is typically assessed using biophysical methods such as surface plasmon resonance or fluorescence polarization, followed by functional degradation assays.
|
| Cell Assay |
The degradation activity of PROTAC BRD9 Degrader-4 is evaluated in BRD9-expressing cancer cell lines using Western blotting or quantitative proteomics to measure BRD9 protein levels after treatment. The compound typically demonstrates potent DC50 values in the low nanomolar range.
|
| Animal Protocol |
N/A; in vivo efficacy studies are typically conducted in mouse xenograft models of BRD9-dependent cancers, evaluating tumor growth inhibition, pharmacokinetics, and biomarker modulation. Such studies are ongoing for this research compound.
|
| ADME/Pharmacokinetics |
The compound has a molecular weight of 768.87 and molecular formula C42H49FN6O7. It is typically stored as a powder at -20degC, away from moisture and light. Soluble in DMSO for in vitro and potential in vivo formulation.
|
| Toxicity/Toxicokinetics |
This product is for research use only, not for human therapeutic or clinical applications. Standard safe handling practices for laboratory chemical reagents should be followed. This degrader is not approved for clinical use.
|
| References | |
| Additional Infomation |
BRD9 is a component of the non-canonical BAF chromatin remodeling complex and is an emerging target in synovial sarcoma, acute myeloid leukemia, and other cancers. PROTAC BRD9 Degrader-4 is a valuable tool for studying BRD9 biology and validating it as a therapeutic target.
|
| Molecular Formula |
C42H49FN6O7
|
|---|---|
| Molecular Weight |
768.87287402153
|
| Exact Mass |
768.364
|
| CAS # |
2633632-34-3
|
| PubChem CID |
156178507
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
56
|
| Complexity |
1430
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCN1C=C(C2=C(C1=O)C=NC=C2)C3=CC(=C(C=C3)O[C@H]4CCN(C[C@@H]4F)CC5CCN(CC5)C(=O)C6=CC(=C(C=C6)OC)N7CCC(=O)NC7=O)OC
|
| InChi Key |
RHYLAIPZKCALML-LRHLLKFHSA-N
|
| InChi Code |
InChI=1S/C42H49FN6O7/c1-4-5-16-48-25-32(30-10-15-44-23-31(30)41(48)52)28-6-9-37(38(22-28)55-3)56-35-13-17-46(26-33(35)43)24-27-11-18-47(19-12-27)40(51)29-7-8-36(54-2)34(21-29)49-20-14-39(50)45-42(49)53/h6-10,15,21-23,25,27,33,35H,4-5,11-14,16-20,24,26H2,1-3H3,(H,45,50,53)/t33-,35-/m0/s1
|
| Chemical Name |
1-[5-[4-[[(3S,4S)-4-[4-(2-butyl-1-oxo-2,7-naphthyridin-4-yl)-2-methoxyphenoxy]-3-fluoropiperidin-1-yl]methyl]piperidine-1-carbonyl]-2-methoxyphenyl]-1,3-diazinane-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~130.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3006 mL | 6.5030 mL | 13.0061 mL | |
| 5 mM | 0.2601 mL | 1.3006 mL | 2.6012 mL | |
| 10 mM | 0.1301 mL | 0.6503 mL | 1.3006 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
